Ibrutinib treatment improves T cell number and function in CLL patients

BACKGROUND. Ibrutinib has been shown to have immunomodulatory effects by inhibiting Bruton’s tyrosine kinase (BTK) and IL-2–inducible T cell kinase (ITK). The relative importance of inhibiting these 2 kinases has not been examined despite its relevance to immune-based therapies. METHODS. Peripheral...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Clin Invest
Huvudupphovsmän: Long, Meixiao, Beckwith, Kyle, Do, Priscilla, Mundy, Bethany L., Gordon, Amber, Lehman, Amy M., Maddocks, Kami J., Cheney, Carolyn, Jones, Jeffrey A., Flynn, Joseph M., Andritsos, Leslie A., Awan, Farrukh, Fraietta, Joseph A., June, Carl H., Maus, Marcela V., Woyach, Jennifer A., Caligiuri, Michael A., Johnson, Amy J., Muthusamy, Natarajan, Byrd, John C.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society for Clinical Investigation 2017
Ämnen:
Clinical Medicine
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5531425/
https://ncbi.nlm.nih.gov/pubmed/28714866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI89756
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk